Commentary: drug-associated atypical femoral fractures (DaAFFs): balancing the facts.
Oxford University Institute of Musculoskeletal Sciences, Oxford OX3 7LD, United Kingdom.
Michael
M
Pazianas
Roger
R
Smith
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000556:secondary; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects*; D004363:Drug Utilization; D005264:Femoral Fractures / Q000139:chemically induced* / Q000453:epidemiology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced / Q000453:epidemiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000453:epidemiology
D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab